Jinhe Biotechnology (002688.SZ) stated on the investor platform on June 18th that the company is actively developing the pet vaccine market, including dog quadrivalent mRNA vaccine, cat quadrivalent vaccine, and horse vaccine, mainly developed by the research and development center in the United States. Fama Wei, the subsidiary in the United States, is the main body of Jinhe Biotechnology's overseas animal vaccine platform, with an international high-end brand image, an international sales network, and leading technological advantages.
金河生物(002688.SZ)：目前在积极布局宠物疫苗市场，包括犬四联mRNA疫苗、猫四联疫苗、以及赛马疫苗等
Jinhe Biotechnology (002688.SZ) is currently actively developing the pet vaccine market, including canine quadrivalent mRNA vaccine, feline quadrivalent vaccine, and horse vaccine.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.